Risk of Myocarditis and Pericarditis among Young Adults following mRNA COVID-19 Vaccinations

There have been reports of cases of myocarditis and pericarditis as rare complications following mRNA COVID-19 vaccinations among young adults. While most reported cases are mild, this potential vaccine safety signal should be closely monitored. Using data from the CDC and the Vaccine Adverse Event Reporting System (VAERS), we calculated the combined reporting rate of myocarditis and pericarditis stratified by age group, sex, vaccine dose, and manufacturer, and compared these rates to the crude background incidence rates. Compared to the general population prior to the administration of the first COVID-19 vaccines in December 2020, we identified a higher-than-expected reporting rate of myocarditis and pericarditis following mRNA vaccination; the risk was higher after a second vaccine dose, higher in males than in females, and decreased with age. The highest risk was seen in males 12-17 years of age with approximately 6 cases per 100,000 second doses. Our findings suggest an increased risk of myocarditis and pericarditis in young males following a second dose of an mRNA COVID-19 vaccine. Since these findings are based on safety signals derived from passive surveillance data, confirmatory epidemiological studies should be undertaken.

Automated summary

There have been reports of rare complications, such as myocarditis and pericarditis, following mRNA COVID-19 vaccinations among young adults. A higher-than-expected reporting rate of these complications has been observed, particularly after the second dose, in males compared to females, and with decreasing risk with age. Confirmatory epidemiological studies should be conducted due to the limitations of passive surveillance data.